|
" A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel. "
Piawah, Sorbarikor; Hyland, Colby; Umetsu, Sarah E; Esserman, Laura J; Rugo, Hope S; Chien, A Jo
| Document Type
|
:
|
AL
|
| Record Number
|
:
|
908919
|
| Doc. No
|
:
|
LA26g4h01g
|
| Title & Author
|
:
|
A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel. [Article]\ Piawah, Sorbarikor; Hyland, Colby; Umetsu, Sarah E; Esserman, Laura J; Rugo, Hope S; Chien, A Jo
|
| Date
|
:
|
2019
|
| Title of Periodical
|
:
|
UCSF
|
| Abstract
|
:
|
Pexidartinib (PLX3397) is a small molecule tyrosine kinase and colony-stimulating factor-1 inhibitor with FDA breakthrough therapy designation for tenosynovial giant-cell tumor, and currently under study in several other tumor types, including breast cancer, non-Hodgkin's lymphoma, and glioblastoma. Here, we report a case of severe drug-induced liver injury requiring liver transplantation due to vanishing bile duct syndrome (VBDS) after exposure to pexidartinib in the I-SPY 2 Trial, a phase 2 multicenter randomized neoadjuvant chemotherapy trial in patients with Stage II-III breast cancer. We also review the current literature on this rare, idiosyncratic, and potentially life-threatening entity.
|
| |